A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome
Primary Purpose
Primary Sjögren's Syndrome
Status
Completed
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
Placebo
RC18 240 mg
RC18 160 mg
Sponsored by

About this trial
This is an interventional treatment trial for Primary Sjögren's Syndrome
Eligibility Criteria
Inclusion Criteria:
- Voluntarily signed informed consent ;
- Patient with primary Sjögren's syndrome according to the European - American consensus group criteria.
- Seropositive at screening for anti-Ro/Sjögren's syndrome type A(SSA) antibodies
- ESSDAI score ≥ 5.
Exclusion Criteria:
- Diagnosis of secondary Sjogren's syndrome, such as rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis and other autoimmune diseases;
- Abnormal laboratory parameters need to be excluded, including but not limited to:
- Immunosuppressive agents were used within 4 weeks prior to randomization.;
- The use of hydroxychloroquine was allowed during the trial, and the pre-randomized drug regimen was stable for less than 12 weeks;
- Use of biological agents for targeted therapy in the first 6 months of randomization;
- Treatment of primary Sjogren's syndrome with traditional Chinese medicine and proprietary Chinese medicine within 4 weeks before randomization;
- The use of saliva-stimulating drugs within 7 days prior to randomization;
- Sodium hyaluronate eye drops, artificial tears can be used, and the stability time of the randomized pre-medication scheme is less than 4 weeks;
- Intravenous immunoglobulin therapy or plasma exchange therapy within 6 months before randomization;
- Infection with herpes zoster or HIV and hepatitis C virus(HCV) antibody positive;
- Currently suffering from active hepatitis or severe liver lesions and history;
- Malignant tumor patients ;
- Combined with involvement of important organs or neuropathy;
- Have participated in any clinical trial in the first 28 days of the initial screening or 5 times half-life period of the study compound (taking the time for the shorter).
- Pregnant , lactating women and men or women who have birth plans during the research;
- Investigator considers candidates not appropriating for the study
Sites / Locations
- Remegen,Ltd.
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Placebo Comparator
Arm Label
RC18 240mg
RC18 160 mg
Placebo
Arm Description
Outcomes
Primary Outcome Measures
The amount of change of European League Against Rheumatism Sjögren's syndrome disease activity(ESSDAI) score compared to the baseline at week 24.
ESSDAI= European League Against Rheumatism Sjögren's syndrome disease activity index score.The ESSDAI includes It includes 12 domains (ie, organ systems: cutaneous,respiratory, renal, articular, muscular,peripheral nervous system (PNS), central nervous system (CNS), haematological, glandular,constitutional,lymphadenopathic,biological).. Each domain is divided into 3-4 levels of activity.The higher the score, the more serious the symptoms ,that is,the worse the results.Subscales are combined by summed.
Secondary Outcome Measures
The amount of change of ESSDAI score compared to the baseline at week 12.
ESSDAI= European League Against Rheumatism Sjögren's syndrome disease activity index score.The ESSDAI includes It includes 12 domains (ie, organ systems: cutaneous,respiratory, renal, articular, muscular,peripheral nervous system (PNS), central nervous system (CNS), haematological, glandular,constitutional,lymphadenopathic,biological).. Each domain is divided into 3-4 levels of activity.The higher the score, the more serious the symptoms ,that is,the worse the results.Subscales are combined by summed.
The amount of change of European League Against Rheumatism Sjögren'sSyndrome Patient Reported Index(ESSPRI) score compared to the baseline at week 12 and week 24
European League Against Rheumatism Sjögren's Syndrome Patient Reported Index.Dryness, pain, somatic and mental fatigue were identified as the main symptoms of patients with primary SS. It was suspected that a single 0-10 numerical scale for each domain was sufficient to assess these symptoms.The higher values represent a worse outcome.Subscales are combined by averaged.
Doctors assess overall changes in disease activity relative to baseline at week 12 and week 24
The measurement tool is Visual Analogue Scale/Score(VAS).The doctor assesses participant's disease activity on a VAS of 0 - 100 mm on the questionnaire form.
Overall patient assessment of disease activity compared to baseline at week 12 and week 24
The measurement tool is Visual Analogue Scale/Score(VAS). The participant assesses his/her own disease activity on a VAS of 0 - 100 mm on the questionnaire form.
Changes in short form(SF)-36 relative to baseline at week 12 and week 24
SF-36=36-item short form. As a concise health questionnaire, SF-36 summarized the quality of life of the subjects from eight aspects: physiological function, physical pain, general health condition, energy, social function, emotional function and mental health.The SF-361 is a self-report, 36 item survey measuring health-related quality-of-life. Thirty-five items are used to construct 8 scales. An additional item measures health transition.The higher values represent a better outcome.Subscales are combined by averaged.
Statistical Analysis of the variation of multidimensional fatigue inventory relative to baseline at week 12 and week 24
Multidimensional Fatigue Inventory.The MFI is a 20-item scale designed to evaluate fi ve dimensions of fatigue: general fatigue, physical fatigue, reduced motivation,reduced activity, and mental fatigue.The higher values represent a worse outcome,Subscales are combined by summed.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04078386
Brief Title
A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome
Official Title
A Phase II Study of RC18, a Recombinant Human B Lymphocyte Stimulator Receptor:Immunoglobulin G( IgG ) Fc Fusion Protein for Injection for the Treatment of Subjects With Primary Sjögren's Syndrome
Study Type
Interventional
2. Study Status
Record Verification Date
January 2022
Overall Recruitment Status
Completed
Study Start Date
November 21, 2019 (Actual)
Primary Completion Date
June 23, 2021 (Actual)
Study Completion Date
October 26, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
RemeGen Co., Ltd.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to initially observe the safety and effectivity of RC18 in Participants with Primary Sjögren's Syndrome.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Primary Sjögren's Syndrome
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
42 (Actual)
8. Arms, Groups, and Interventions
Arm Title
RC18 240mg
Arm Type
Experimental
Arm Title
RC18 160 mg
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Biological
Intervention Name(s)
Placebo
Intervention Description
Patients received the test group Placebo weekly administered subcutaneously for 24 times.
Intervention Type
Biological
Intervention Name(s)
RC18 240 mg
Intervention Description
Arm Description:Patients received the test group RC18 240mg weekly administered subcutaneously for 24 times.
Intervention Type
Biological
Intervention Name(s)
RC18 160 mg
Intervention Description
Patients received the test group RC18 160mg weekly administered subcutaneously for 24 times.
Primary Outcome Measure Information:
Title
The amount of change of European League Against Rheumatism Sjögren's syndrome disease activity(ESSDAI) score compared to the baseline at week 24.
Description
ESSDAI= European League Against Rheumatism Sjögren's syndrome disease activity index score.The ESSDAI includes It includes 12 domains (ie, organ systems: cutaneous,respiratory, renal, articular, muscular,peripheral nervous system (PNS), central nervous system (CNS), haematological, glandular,constitutional,lymphadenopathic,biological).. Each domain is divided into 3-4 levels of activity.The higher the score, the more serious the symptoms ,that is,the worse the results.Subscales are combined by summed.
Time Frame
week 24
Secondary Outcome Measure Information:
Title
The amount of change of ESSDAI score compared to the baseline at week 12.
Description
ESSDAI= European League Against Rheumatism Sjögren's syndrome disease activity index score.The ESSDAI includes It includes 12 domains (ie, organ systems: cutaneous,respiratory, renal, articular, muscular,peripheral nervous system (PNS), central nervous system (CNS), haematological, glandular,constitutional,lymphadenopathic,biological).. Each domain is divided into 3-4 levels of activity.The higher the score, the more serious the symptoms ,that is,the worse the results.Subscales are combined by summed.
Time Frame
week 12
Title
The amount of change of European League Against Rheumatism Sjögren'sSyndrome Patient Reported Index(ESSPRI) score compared to the baseline at week 12 and week 24
Description
European League Against Rheumatism Sjögren's Syndrome Patient Reported Index.Dryness, pain, somatic and mental fatigue were identified as the main symptoms of patients with primary SS. It was suspected that a single 0-10 numerical scale for each domain was sufficient to assess these symptoms.The higher values represent a worse outcome.Subscales are combined by averaged.
Time Frame
week 12,24
Title
Doctors assess overall changes in disease activity relative to baseline at week 12 and week 24
Description
The measurement tool is Visual Analogue Scale/Score(VAS).The doctor assesses participant's disease activity on a VAS of 0 - 100 mm on the questionnaire form.
Time Frame
week 12,24
Title
Overall patient assessment of disease activity compared to baseline at week 12 and week 24
Description
The measurement tool is Visual Analogue Scale/Score(VAS). The participant assesses his/her own disease activity on a VAS of 0 - 100 mm on the questionnaire form.
Time Frame
week 12,24
Title
Changes in short form(SF)-36 relative to baseline at week 12 and week 24
Description
SF-36=36-item short form. As a concise health questionnaire, SF-36 summarized the quality of life of the subjects from eight aspects: physiological function, physical pain, general health condition, energy, social function, emotional function and mental health.The SF-361 is a self-report, 36 item survey measuring health-related quality-of-life. Thirty-five items are used to construct 8 scales. An additional item measures health transition.The higher values represent a better outcome.Subscales are combined by averaged.
Time Frame
week 12,24
Title
Statistical Analysis of the variation of multidimensional fatigue inventory relative to baseline at week 12 and week 24
Description
Multidimensional Fatigue Inventory.The MFI is a 20-item scale designed to evaluate fi ve dimensions of fatigue: general fatigue, physical fatigue, reduced motivation,reduced activity, and mental fatigue.The higher values represent a worse outcome,Subscales are combined by summed.
Time Frame
week 12,24
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Voluntarily signed informed consent ;
Patient with primary Sjögren's syndrome according to the European - American consensus group criteria.
Seropositive at screening for anti-Ro/Sjögren's syndrome type A(SSA) antibodies
ESSDAI score ≥ 5.
Exclusion Criteria:
Diagnosis of secondary Sjogren's syndrome, such as rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis and other autoimmune diseases;
Abnormal laboratory parameters need to be excluded, including but not limited to:
Immunosuppressive agents were used within 4 weeks prior to randomization.;
The use of hydroxychloroquine was allowed during the trial, and the pre-randomized drug regimen was stable for less than 12 weeks;
Use of biological agents for targeted therapy in the first 6 months of randomization;
Treatment of primary Sjogren's syndrome with traditional Chinese medicine and proprietary Chinese medicine within 4 weeks before randomization;
The use of saliva-stimulating drugs within 7 days prior to randomization;
Sodium hyaluronate eye drops, artificial tears can be used, and the stability time of the randomized pre-medication scheme is less than 4 weeks;
Intravenous immunoglobulin therapy or plasma exchange therapy within 6 months before randomization;
Infection with herpes zoster or HIV and hepatitis C virus(HCV) antibody positive;
Currently suffering from active hepatitis or severe liver lesions and history;
Malignant tumor patients ;
Combined with involvement of important organs or neuropathy;
Have participated in any clinical trial in the first 28 days of the initial screening or 5 times half-life period of the study compound (taking the time for the shorter).
Pregnant , lactating women and men or women who have birth plans during the research;
Investigator considers candidates not appropriating for the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Xiaofeng Zeng, M.D.
Organizational Affiliation
Peking Union Medical College Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Remegen,Ltd.
City
Yantai
State/Province
Shandong
ZIP/Postal Code
264006
Country
China
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome
We'll reach out to this number within 24 hrs